SCHEMBL6831069

SCHEMBL6831069

Cn1cc2c(n1)-c1c(C(=O)Nc3cccnc3)c[nH]c1CCC2

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 7/20 0.53
CYP11B2 P19099 3/20 0.42
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.39
MCL1 Q07820 2/20 0.39
KCNMA1 Q12791 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6834167 0.88 NAMPT (0.55) NAMPTCYP11B2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6833501 0.87 NAMPT (0.45) NAMPTCYP11B2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6834084 0.86 NAMPT (0.44) NAMPTALDH1A1SMN1; SMN2KDM4ETSHR
SCHEMBL6834466 0.84 KMT2A (0.37) NAMPTALDH1A1SMN1; SMN2KDM4ETSHR
SCHEMBL6303008 0.83 ALDH1A1 (0.44) NAMPTCYP11B2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6834487 0.82 GAA (0.43) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL6309958 0.82 ALDH1A1 (0.42) NAMPTCYP11B2ALDH1A1KDM4ETSHR
SCHEMBL6834309 0.81 LMNA (0.42) ALDH1A1SMN1; SMN2KDM4EMEN1HPGD
SCHEMBL7221648 0.80 JAK2 (0.40) ALDH1A1MEN1KMT2ARAB9AGAA
SCHEMBL7217055 0.80 NPC1 (0.48) SMN1; SMN2KDM4ETSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 US claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 NAMPT 2347/4885CYP11B2 336/4885ALDH1A1 1197/4885
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 NAMPT 2347/4885CYP11B2 336/4885ALDH1A1 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.